63,270 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Cornerstone Select Advisors LLC

Cornerstone Select Advisors LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 63,270 shares of the biopharmaceutical company's stock, valued at approximately $1,904,000. TG Therapeutics makes up 1.8% of Cornerstone Select Advisors LLC's holdings, making the stock its 12th largest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of TGTX. Arizona State Retirement System raised its position in shares of TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the period. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares in the last quarter. Brookstone Capital Management boosted its stake in shares of TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 624 shares in the last quarter. Finally, Daymark Wealth Partners LLC lifted its position in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock worth $1,249,000 after purchasing an additional 689 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on TGTX shares. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Stock Up 1.2%

Shares of TGTX traded up $0.41 during midday trading on Monday, hitting $34.05. The stock had a trading volume of 1,055,316 shares, compared to its average volume of 3,014,735. The company has a 50 day simple moving average of $38.90 and a two-hundred day simple moving average of $33.70. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a market cap of $5.41 billion, a price-to-earnings ratio of -341.05 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same period in the prior year, the business earned ($0.07) EPS. The business's revenue for the quarter was up 90.4% compared to the same quarter last year. On average, analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.